Shambavi Richard

1.6k total citations
64 papers, 708 citations indexed

About

Shambavi Richard is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Shambavi Richard has authored 64 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 33 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Shambavi Richard's work include Multiple Myeloma Research and Treatments (47 papers), CAR-T cell therapy research (25 papers) and Protein Degradation and Inhibitors (14 papers). Shambavi Richard is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), CAR-T cell therapy research (25 papers) and Protein Degradation and Inhibitors (14 papers). Shambavi Richard collaborates with scholars based in United States, United Kingdom and Canada. Shambavi Richard's co-authors include Joshua Richter, Sundar Jagannath, Deepu Madduri, Hearn Jay Cho, Ajai Chari, Samir Parekh, Larysa Sanchez, Guido Lancman, Santiago Thibaud and Adriana Rossi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Shambavi Richard

57 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shambavi Richard United States 15 394 353 268 114 99 64 708
Leyla Shune United States 13 410 1.0× 343 1.0× 210 0.8× 99 0.9× 27 0.3× 107 688
Xia Mao China 16 512 1.3× 194 0.5× 235 0.9× 180 1.6× 53 0.5× 66 741
Hisham Abdel‐Azim United States 17 275 0.7× 277 0.8× 294 1.1× 277 2.4× 19 0.2× 68 966
Simona Lapusan France 15 271 0.7× 350 1.0× 146 0.5× 109 1.0× 47 0.5× 33 676
Emily Curran United States 16 201 0.5× 220 0.6× 278 1.0× 263 2.3× 23 0.2× 42 765
Kentaro Narita Japan 15 246 0.6× 257 0.7× 176 0.7× 43 0.4× 58 0.6× 96 677
Kathleen Dorritie United States 15 466 1.2× 179 0.5× 166 0.6× 216 1.9× 36 0.4× 45 773
Ofrat Beyar‐Katz Israel 15 444 1.1× 136 0.4× 166 0.6× 179 1.6× 14 0.1× 41 755
Joshua Richter United States 22 863 2.2× 897 2.5× 660 2.5× 357 3.1× 261 2.6× 139 1.6k
Andreas Poschenrieder Germany 10 319 0.8× 86 0.2× 178 0.7× 167 1.5× 216 2.2× 13 732

Countries citing papers authored by Shambavi Richard

Since Specialization
Citations

This map shows the geographic impact of Shambavi Richard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shambavi Richard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shambavi Richard more than expected).

Fields of papers citing papers by Shambavi Richard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shambavi Richard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shambavi Richard. The network helps show where Shambavi Richard may publish in the future.

Co-authorship network of co-authors of Shambavi Richard

This figure shows the co-authorship network connecting the top 25 collaborators of Shambavi Richard. A scholar is included among the top collaborators of Shambavi Richard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shambavi Richard. Shambavi Richard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aleman, Adolfo, Erin Moshier, Adriana Rossi, et al.. (2025). Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy. Clinical Cancer Research. 31(20). 4333–4344. 1 indexed citations
2.
3.
Sanchez, Larysa & Shambavi Richard. (2025). Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies. Seminars in Hematology. 62(1). 31–37. 1 indexed citations
4.
Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505. 2 indexed citations
5.
Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2024). MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Advances. 9(1). 176–179.
6.
7.
Bar, Noffar, Andrew J. Yee, Binod Dhakal, et al.. (2024). P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series. Clinical Lymphoma Myeloma & Leukemia. 24. S44–S45. 1 indexed citations
8.
Hansen, Doris K., et al.. (2024). P-123 Patient Preferences for use of CAR-T therapy as an Early Line Treatment in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S112–S113. 1 indexed citations
9.
Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations
10.
Raab, Marc S., Jonathan L. Kaufman, Shambavi Richard, et al.. (2023). Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study. Blood. 142(Supplement 1). 3334–3334. 2 indexed citations
11.
12.
Mouhieddine, Tarek H., Weijia Fu, Erin Moshier, et al.. (2023). Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy. Blood. 142(Supplement 1). 92–92. 2 indexed citations
13.
Thibaud, Santiago, Ajai Chari, Joshua Richter, et al.. (2023). Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma. Blood. 142(Supplement 1). 2002–2002. 2 indexed citations
14.
Restrepo, Paula, Sherry Bhalla, Yogita Ghodke‐Puranik, et al.. (2022). A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precision Oncology. 6(6). e2200147–e2200147. 14 indexed citations
15.
Thibaud, Santiago, Oliver Van Oekelen, Tarek H. Mouhieddine, et al.. (2022). Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy. Blood. 140(Supplement 1). 614–616. 17 indexed citations
16.
Sindhu, Kunal K., Erin Moshier, Joshua Richter, et al.. (2021). The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(3). 192–197. 6 indexed citations
17.
Lancman, Guido, Samantha E. Jacobs, John T. Doucette, et al.. (2021). Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(5). e470–e476. 18 indexed citations
18.
Restrepo, Paula, Sherry Bhalla, Adolfo Aleman, et al.. (2021). Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature. Blood. 138(Supplement 1). 457–457. 1 indexed citations
19.
Richard, Shambavi, Sundar Jagannath, Hearn Jay Cho, et al.. (2020). A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Review of Hematology. 14(1). 31–45. 6 indexed citations
20.
Wadhwa, Nand K., et al.. (2011). Reversible left ventricular dysfunction and acute kidney injury in a patient with nonamyloid light chain deposition disease. Clinical Nephrology. 78(12). 501–505. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leyla Shune Breakdown of academic impact, for papers by Xia Mao Breakdown of academic impact, for papers by Hisham Abdel‐Azim Breakdown of academic impact, for papers by Simona Lapusan Breakdown of academic impact, for papers by Emily Curran Breakdown of academic impact, for papers by Kentaro Narita Breakdown of academic impact, for papers by Kathleen Dorritie Breakdown of academic impact, for papers by Ofrat Beyar‐Katz Breakdown of academic impact, for papers by Joshua Richter Breakdown of academic impact, for papers by Andreas Poschenrieder
Rankless by CCL
2026